Accelerated Article Preview

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

Received: 30 December 2021

Accepted: 14 January 2022

Accelerated Article Preview Published
online 14 January 2022

Cite this article as: Gao, Y. . et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. *Nature Medicine* <https://doi.org/10.1038/s41591-022-01700-x> (2022).

Yu Gao, Curtis Cai, Alba Grifoni, Thomas R. Müller, Julia Niessl, Anna Olofsson, Marion Humbert, Lotta Hansson, Anders Österborg, Peter Bergman, Puran Chen, Annika Olsson, Johan K. Sandberg, Daniela Weiskopf, David A. Price, Hans-Gustaf Ljunggren, Annika C. Karlsson, Alessandro Sette, Soo Aleman & Marcus Buggert

This is a PDF file of a peer-reviewed paper that has been accepted for publication.

Although unedited, the content has been subjected to preliminary formatting.

Nature Medicine is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

Yu Gao^{1,11}, Curtis Cai^{1,11}, Alba Grifoni², Thomas R. Müller¹, Julia Niessl¹, Anna Olofsson³, Marion Humbert³, Lotta Hansson^{4,5}, Anders Österborg^{4,5}, Peter Bergman^{3,6}, Puran Chen¹, Annika Olsson⁶, Johan K. Sandberg¹, Daniela Weiskopf², David A. Price^{7,8}, Hans-Gustaf Ljunggren¹, Annika C. Karlsson³, Alessandro Sette^{2,9}, Soo Aleman^{6,10}, Marcus Buggert^{1,*}

¹Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden

²Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA

³Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, Stockholm, Sweden

⁴Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

⁵Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

⁶Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden

⁷Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK

⁸Systems Immunity Research Institute, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK

⁹Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, USA

¹⁰Department of Medicine Huddinge, Infectious Diseases and Dermatology Unit, Karolinska Institutet, Stockholm, Sweden

¹¹These authors contributed equally to this work.

*Correspondence: marcus.buggert@ki.se

ABSTRACT

The emergence of the SARS-CoV-2 variant-of-concern Omicron (B.1.1.529) has destabilized global efforts to control the impact of COVID-19. Recent data have suggested that B.1.1.529 can readily infect people with naturally acquired or vaccine-induced immunity, facilitated in some cases by viral escape from antibodies that neutralize ancestral SARS-CoV-2. However, severe disease appears to be relatively uncommon in such individuals, highlighting a potential role for other components of the adaptive immune system. We report here that SARS-CoV-2 spike-specific CD4⁺ and CD8⁺ T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against B.1.1.529. The median relative frequencies of SARS-CoV-2 spike-specific CD4⁺ T cells that cross-recognized B.1.1.529 in previously infected or BNT162b2-vaccinated individuals were 84% and 91%, respectively, and the corresponding median relative frequencies for SARS-CoV-2 spike-specific CD8⁺ T cells were 70% and 92%, respectively. Pairwise comparisons across groups further revealed that SARS-CoV-2 spike-reactive CD4⁺ and CD8⁺ T cells were functionally and phenotypically similar in response to the ancestral strain or B.1.1.529. Collectively, our data indicate that established SARS-CoV-2 spike-specific CD4⁺ and CD8⁺ T cell responses, especially after BNT162b2 vaccination, remain largely intact against B.1.1.529.

MAIN

Natural infection with SARS-CoV-2 and vaccination with mRNA constructs encoding the viral spike protein typically generate effective immunity against COVID-19. However, the current pandemic has been fueled by the continual emergence of variants-of-concern (VOCs), such as Omicron (B.1.1.529). Recent data indicate that B.1.1.529 is more transmissible than previous VOCs¹. This phenotype can be explained by key mutations in the receptor-binding domain, which confer enhanced affinity for the ACE2 receptor². Another major concern is that B.1.1.529 harbors a large number of additional mutations in the spike protein that could feasibly subvert immune recognition³. In line with this possibility, emerging reports have shown that neutralizing antibodies elicited against the ancestral Wuhan reference strain, either in the context of infection or vaccination, are less able to combat B.1.1.529^{2,4}. These observations likely align with the propensity of B.1.1.529 to cause breakthrough infections^{5,6}.

Preliminary data suggest that breakthrough infections with B.1.1.529 are associated with a lower risk of hospitalization and/or severe illness compared with the Delta VOC (B.1.617.2)^{7,8}. One possible inference from these clinical observations is that additional immune mechanisms beyond antibody production attenuate the course of infection with B.1.1.529. Previous studies have demonstrated that robust CD4⁺ and CD8⁺ T cell responses are induced following SARS-CoV-2 infection or vaccination⁹⁻¹⁵. Several lines of evidence further suggest that CD4⁺ and CD8⁺ T cell responses can modulate disease severity in humans and suppress viral replication in animal models¹⁶⁻¹⁹. However, it has remained unclear to what extent ancestral SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells cross-recognize B.1.1.529, especially given the unprecedented number of mutations in the spike protein, which likely shift the antigenic landscape more profoundly in relation to antecedent VOCs²⁰.

To address this question, we collected peripheral blood mononuclear cells from vaccinated individuals 6 months after a second dose of the Pfizer/BioNTech mRNA BNT162b2

formulation (median age = 53 years, $n = 23$ female and 17 male), individuals in the convalescent phase 9 months after mild (median age = 54 years, $n = 8$ female and 18 male) or severe COVID-19 (median age = 58 years, $n = 3$ female and 19 male), and seronegative individuals (unclassified demographics, total $n = 48$) (Supplementary Table 1). Cells were stimulated in parallel with overlapping peptide pools spanning the entire spike protein sequences of the Wuhan reference strain (wildtype) or B.1.1.529. Activation-induced marker assays were used to quantify spike-specific CD4⁺ T cell responses via the upregulation of CD69 and CD40L (CD154) and spike-specific CD8⁺ T cell responses via the upregulation of CD69 and 4-1BB (CD137) (Extended Data Fig. 1a).

The overall magnitude of the SARS-CoV-2 spike-specific CD4⁺ T cell response against B.1.1.529 showed a median reduction of 9% in BNT162b2-vaccinated individuals and a median reduction of 16% in convalescent individuals relative to the wildtype response (Fig. 1a, b). The corresponding response frequencies, defined using a threshold stimulation index, were also slightly lower for B.1.1.529 (Fig. 1c). Pairwise comparisons further revealed maximum reductions in magnitude of 58% among BNT162b2-vaccinated individuals, 56% among convalescent individuals, and 75% among seronegative individuals for SARS-CoV-2 spike-specific CD4⁺ T cell responses against B.1.1.529 *versus* wildtype (Fig. 1d). These results were validated using independently synthesized peptide pools spanning each spike protein (Extended Data Fig. 1b).

To extend these findings, we investigated the phenotypic characteristics of SARS-CoV-2 spike-specific CD4⁺ T cells that cross-recognized B.1.1.529, with a particular focus on markers of T helper polarization (CCR4, CCR6, CXCR3, CXCR5) and memory differentiation (CCR7, CD45RA). No significant differences in T helper polarization were detected across intragroup comparisons of SARS-CoV-2 spike-specific CD4⁺ T cell responses against B.1.1.529 *versus* wildtype (Fig. 1e). Central memory T (T_{CM}) cells predominated among SARS-CoV-2 spike-specific CD4⁺ T cells in BNT162b2-vaccinated, convalescent, and

seronegative individuals, but again, no significant differences in subset composition were detected across intragroup comparisons of SARS-CoV-2 spike-specific CD4⁺ T cell responses against B.1.1.529 *versus* wildtype (Fig. 1f). We also assessed the functionality of SARS-CoV-2 spike-specific CD4⁺ T cells in BNT162b2-vaccinated individuals, measuring the intracellular expression of IFN- γ , TNF, and IL-2 alongside CD69 and CD154. No significant differences in the ability of SARS-CoV-2 spike-specific CD4⁺ T cells to deploy multiple functions were apparent in response to stimulation with peptides representing B.1.1.529 *versus* wildtype (Fig. 1g).

The overall magnitude of the SARS-CoV-2 spike-specific CD8⁺ T cell response against B.1.1.529 showed a median reduction of 8% in BNT162b2-vaccinated individuals and a median reduction of 30% in convalescent individuals relative to the wildtype response (Fig. 2a, b). These differences were mirrored in the corresponding response frequencies, defined using a threshold stimulation index (Fig. 2c). Pairwise comparisons further revealed maximum reductions in magnitude of 55% among BNT162b2-vaccinated individuals, 63% among convalescent individuals, and 60% among seronegative individuals for SARS-CoV-2 spike-specific CD8⁺ T cell responses against B.1.1.529 *versus* wildtype (Fig. 2d). These results were again validated using independently synthesized peptide pools spanning each spike protein (Extended Data Fig. 1c).

In further experiments, we investigated the phenotypic characteristics of SARS-CoV-2 spike-specific CD8⁺ T cells that cross-recognized B.1.1.529, focusing on classic markers of memory differentiation (CCR7, CD45RA). Late effector memory T (T_{EMRA}) cells predominated among SARS-CoV-2 spike-specific CD8⁺ T cells in BNT162b2-vaccinated, convalescent, and seronegative individuals, but no significant differences in subset composition were detected across intragroup comparisons of SARS-CoV-2 spike-specific CD8⁺ T cell responses against B.1.1.529 *versus* wildtype (Fig. 2e). We also assessed the functionality of SARS-CoV-2 spike-specific CD8⁺ T cells in BNT162b2-vaccinated individuals, measuring the intracellular

expression of granzyme B, IFN- γ , TNF, and IL-2 alongside CD69 and CD137. Akin to the corresponding analyses of SARS-CoV-2 spike-specific CD4⁺ T cells, no significant differences in the ability of SARS-CoV-2 spike-specific CD8⁺ T cells to deploy multiple functions were apparent in response to stimulation with peptides representing B.1.1.529 *versus* wildtype (Fig. 2f).

Finally, we merged the SARS-CoV-2 spike-specific CD4⁺ and CD8⁺ T cell data by group, aiming to evaluate cross-recognition *en masse*. The overall magnitude of the combined SARS-CoV-2 spike-specific CD4⁺ and CD8⁺ T cell response against B.1.1.529 was significantly lower in convalescent individuals but not in BNT162b2-vaccinated individuals relative to the wildtype response (Extended Data Fig. 1d). Although potentially reflecting differences in the chronology and/or context of antigen exposure, these results suggest that ancestral SARS-CoV-2 spike-specific CD4⁺ and CD8⁺ T cells elicited by natural infection provide comprehensive but relatively incomplete coverage against B.1.1.529.

The current global pandemic has been destabilized by the recent emergence of B.1.1.529, which continues to spread rapidly and supersede other VOCs. Our collective data indicate that SARS-CoV-2 spike-specific CD4⁺ and CD8⁺ T cells elicited by BNT162b2 vaccination or prior infection remain largely intact against B.1.1.529. Alongside intrinsic viral factors, such as altered tropism and decreased replication in the lower respiratory tract²¹, such heterologous immune reactivity may explain why severe disease appears to be relatively uncommon after infection with this particular VOC. Moreover, the degree of cross-reactivity varied to some extent among individuals, most likely as a consequence of genetically encoded differences in antigen presentation, which could further modulate clinical outcomes associated with B.1.1.529. It should be noted that we did not formally assess cytotoxic functions beyond the expression of granzyme B and that our evaluations were confined to peripheral blood samples, which do not necessarily reflect the entirety of the cellular immune response against SARS-CoV-2²². In addition, we found that SARS-CoV-2 spike-specific

158 CD4⁺ and CD8⁺ T cells cross-recognized B.1.1.529 less comprehensively in convalescent
159 *versus* BNT162b2-vaccinated individuals, suggesting that booster immunization may provide
160 benefits that extend beyond the induction of broadly neutralizing antibodies to enhance
161 natural protection against recurrent episodes of COVID-19².

ACKNOWLEDGEMENTS

This project was supported by grants from the SciLifeLab National COVID-19 Research Program, financed by the Knut and Alice Wallenberg Foundation, the Swedish Research Council, Nordstjernan AB, Region Stockholm, and the Karolinska Institutet. J.N. was supported by an EMBO Postdoctoral Fellowship (ALTF 1062-2020). D.A.P. was supported by the National Institute for Health Research (COV-LT2-0041). A.C.K. was supported by the Swedish Research Council (2020-02033), the Centrum för Innovativ Medicin (2019-0495), and the Karolinska Institutet (2019-00931). M.B. was supported by the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Karolinska Institutet, the Swedish Society of Medicine, the Swedish Cancer Society, the Swedish Childhood Cancer Fund, the Åke Wibergs Stiftelse, and the Jonas Söderquist Stiftelse. This project was also supported in part by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. 75N93021C00016 (to A.S.) and contract no. 75N9301900065 (to D.W. and A.S.). We thank the COVAXID clinical study group, Piotr Nowak, Edvard Smith, Per Ljungman, Stephan Mielke, Gunnar Söderdahl and Ola Blennow, for their involvement in the COVAXID study and recruitment of vaccinated healthy study subjects.

AUTHOR CONTRIBUTIONS STATEMENT

Conceptualization: Y.G., C.C., J.K.S., D.A.P., H.G.L., A.C.K., A.S., S.A., M.B.

Sample collection: Y.G., C.C., T.R.M., J.N., L.H., A.Ö., P.B., P.C., A.Ols., H.G.L., S.A., M.B.

Investigation: Y.G., C.C., A.G., A.Olo., M.H., M.B.

Formal analysis: Y.G., C.C.

Visualization: Y.G., C.C., M.B.

Resources: A.G., J.K.S., D.W., H.G.L., A.C.K., A.S., S.A., M.B.

Funding acquisition: D.A.P., H.G.L., A.S., S.A., M.B.

Supervision: J.K.S., H.G.L., S.A., M.B.

Writing—original draft: Y.G., C.C., D.A.P., M.B.

Writing—review and editing: Y.G., C.C., A.G., T.R.M., J.N., A.Ö., P.B., J.K.S., D.A.P., H.G.L.,
A.C.K., S.A., M.B.

COMPETING INTERESTS STATEMENT

A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress, and Repertoire, and the La Jolla Institute has filed patents to protect various aspects of the T cell epitope and vaccine design work. S.A. has received honoraria from Gilead, AbbVie, MSD, and Biogen and research grants from Gilead and AbbVie. M.B. is a consultant for Oxford Immunotec. The other authors declare no conflicts of interest.

FIGURE LEGENDS

Fig. 1. Cross-reactive CD4⁺ T cell responses against B.1.1.529.

a, Representative flow cytometry plots showing spike-specific CD4⁺ T cell responses (CD69⁺CD154⁺) to peptide pools representing wildtype SARS-CoV-2 (WT) or B.1.1.529. **b**, Frequencies of all spike-specific CD4⁺ T cells in BNT162b2-vaccinated, convalescent, and seronegative individuals. Numbers indicate median reduction in the frequency of detected responses. Comparisons used two sided Wilcoxon signed rank tests. **P* = 0.012. ns, not significant. **c**, Stimulation indices calculated as fold change in frequency relative to the negative control. Numbers indicate the percentage of individuals with a detectable response. **d**, Cross-reactive responses depicted on an individual basis as percent B.1.1.529/WT. **e**, Helper polarization of spike-specific CD4⁺ T cells with representative gating and dot plots showing the distribution of subsets across individuals with detectable responses. Pie charts show the mean frequency of each subset across all individuals in each group. **f**, Canonical memory differentiation profiles of spike-specific CD4⁺ T cells with representative gating and dot plots showing the distribution of subsets across individuals with detectable responses. **g**, Functional profiles of spike-specific CD4⁺ T cell responses in BNT162b2-vaccinated

individuals with representative gating and pie charts showing the mean frequency for each combination. Polyfunctional responses were compared using a permutation test. Data in dot plots are shown as median $\pm$ IQR. Each dot represents one donor.

Fig. 2. Cross-reactive CD8⁺ T cell responses against B.1.1.529.

a, Representative flow cytometry plots showing spike-specific CD8⁺ T cell responses (CD69⁺CD137⁺) to peptide pools representing wildtype SARS-CoV-2 (WT) or B.1.1.529. **b**, Frequencies of all spike-specific CD8⁺ T cells in BNT162b2-vaccinated, convalescent, and seronegative individuals. Numbers indicate median reduction in the frequency of detected responses. Comparisons used two sided Wilcoxon signed rank tests. ns, not significant. **c**, Stimulation indices calculated as fold change in frequency relative to the negative control. Numbers indicate the percentage of individuals with a detectable response. **d**, Cross-reactive responses depicted on an individual basis as percent B.1.1.529/WT. **e**, Canonical memory differentiation profiles of spike-specific CD8⁺ T cells with representative gating and dot plots showing the distribution of subsets across individuals with detectable responses. **f**, Functional profiles of spike-specific CD8⁺ T cells in BNT162b2-vaccinated individuals with representative gating and pie charts showing the mean frequency for each combination. Polyfunctional responses were compared using a permutation test. Data in bar charts are shown as mean $\pm$ 95% confidence intervals, and data in dot plots are shown as median $\pm$ IQR. Each dot represents one donor. GrzB, granzyme B; ns, not significant.

REFERENCES

1. Dyer, O. Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show. *BMJ* **375**, n3104 (2021).
2. Cameroni, E., *et al.* Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. *bioRxiv* (2021).
3. <https://www.ecdc.europa.eu/sites/default/files/documents/threat-assessment-covid-19-emergence-sars-cov-2-variant-omicron-december-2021.pdf>.
4. Liu L *et al.*, Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. *Nature* **23 December 2021** (2021).
5. Collie, S., Champion, J., Moultrie, H., Bekker, L.G. & Gray, G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. *N Engl J Med* (2021).
6. Goga, A., *et al.* Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26.COVS.2 vaccine trial, South Africa. *MedRxiv* (2021).
7. Neil Ferguson, A.G., Wes Hinsley and Erik Volz on behalf of the Imperial College COVID-19 response team. Report 50: Hospitalisation risk for Omicron cases in England. (2021).
8. Wolter N. *et al.*, Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa. *bioRxiv* (2021).
9. Braun, J., *et al.* SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* **587**, 270-274 (2020).
10. Grifoni, A., *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415 (2020).
11. Kalimuddin, S., *et al.* Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. *Med (N Y)* **2**, 682-688 e684 (2021).
12. Le Bert, N., *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* **584**, 457-462 (2020).
13. Oberhardt, V., *et al.* Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. *Nature* **597**, 268-273 (2021).
14. Peng, Y., *et al.* Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat Immunol* **21**, 1336-1345 (2020).
15. Sekine, T., *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell* **183**, 158-168 e114 (2020).

- 272 16. Israelow, B., *et al.* Adaptive immune determinants of viral clearance and protection in
273 mouse models of SARS-CoV-2. *Sci Immunol* **6**, eabl4509 (2021).
- 274 17. McMahan, K., *et al.* Correlates of protection against SARS-CoV-2 in rhesus
275 macaques. *Nature* **590**, 630-634 (2021).
- 276 18. Rydzynski Moderbacher, C., *et al.* Antigen-Specific Adaptive Immunity to SARS-CoV-
277 2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell* **183**, 996-
278 1012 e1019 (2020).
- 279 19. Tan, A.T., *et al.* Early induction of functional SARS-CoV-2-specific T cells associates
280 with rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep* **34**,
281 108728 (2021).
- 282 20. Tarke, A., *et al.* Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T
283 cell reactivity in infected or vaccinated individuals. *Cell Rep Med* **2**, 100355 (2021).
- 284 21. Meng B, *et al.* SARS-CoV-2 Omicron spike mediated immune escape, infectivity and
285 cell-cell fusion. *bioRxiv* (2021).
- 286 22. Niessl, J., *et al.* Identification of resident memory CD8(+) T cells with functional
287 specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. *Sci*
288 *Immunol* **6**, eabk0894 (2021).

METHODS

Samples

Healthy individual volunteers ($n = 40$) were sampled 6 months after a second dose of the BNT162b2 vaccine (Pfizer/BioNTech) as part of a clinical trial registered at EudraCT (2021-000175-37)¹. Two standard doses of the vaccine were administered with an interval of 21 days. The study was approved by the Swedish Medical Product Agency (ID 5.1-2021-5881). Additional samples ($n = 15$) were collected 3 months after the second dose for validation purposes (Extended Data Fig. 1). Convalescent individual volunteers were sampled 9 months after RT-PCR-verified infection with SARS-CoV-2 leading to mild (non-hospitalized, $n = 26$) or severe (hospitalized, $n = 22$) disease during the first wave of the pandemic in March–April 2020, before the emergence of the Alpha, Beta, and Delta VOCs. None of these individuals had received a COVID-19 vaccine at the time of sample collection. Seronegative volunteer samples were acquired from healthy blood donors in late 2020. The absence of spike-specific antibodies was confirmed using an Anti-SARS-CoV-2 S Immunoassay (Roche). Cohort details are summarized in Supplementary Table 1. All participants provided written informed consent in accordance with the principles of the Declaration of Helsinki. Convalescent and seronegative cohorts were approved by the Regional Ethics Committee in Stockholm, Sweden. Population characteristics of each cohort were not considered and did not factor in for inclusion into this study. Peripheral blood mononuclear cells (PBMCs) were isolated via standard density gradient centrifugation and cryopreserved in fetal bovine serum (FBS) containing 10% dimethyl sulfoxide (DMSO).

Peptides

Overlapping peptides were designed to span the entire spike protein sequence of SARS-CoV-2 corresponding to the ancestral Wuhan strain (wildtype) or B.1.1.529. Test peptides comprising 15mers overlapping by 10 amino acids were synthesized as crude material for functional screens (TC Peptide Lab). Validation peptides comprising 20mers overlapping by

10 amino acids were synthesized to an equivalent specification (Sigma-Aldrich). All peptides were reconstituted in DMSO, diluted to stock concentrations of 100 µg/ml in phosphate-buffered saline (PBS), and stored at -20 °C.

Activation-induced marker assays

PBMCs were thawed quickly, resuspended in RPMI 1640 containing 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin (complete medium) in the presence of DNase I (10 U/ml, Sigma-Aldrich), and rested at 1×10^6 cells per well in 96-well U-bottom plates (Corning) for 4 h at 37 °C. The medium was then supplemented with anti-CXCR5-BB515 and anti-CD40 (unconjugated), followed 15 min later by the relevant peptide pools (1 µg/ml/peptide). Negative control wells contained equivalent DMSO. After 12 h, cells were washed in PBS supplemented with 2% FBS and 2 mM EDTA (FACS buffer) and stained with anti-CCR4/CD194-BB700, anti-CCR6/CD196-BUV737, anti-CCR7-APC-Cy7, and anti-CXCR3-AF647 for 10 min at 37 °C. Additional surface stains were performed for 30 min at room temperature in the presence of Brilliant Stain Buffer Plus (BD Biosciences). Viable cells were identified by exclusion using a LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Thermo Fisher Scientific). Stained cells were washed in FACS buffer, fixed in PBS containing 1% paraformaldehyde (PFA, Biotium), and acquired using a FACSymphony A5 (BD Biosciences). The gating strategy is shown in Extended Data Fig. 1. All flow cytometry reagents are detailed in Supplementary Table 2.

Intracellular cytokine staining

PBMCs were thawed quickly, resuspended in complete medium in the presence of DNase I (10 U/ml, Sigma-Aldrich), and rested at 1×10^6 cells/well in 96-well U-bottom plates (Corning) for 4 h at 37 °C. The medium was then supplemented with anti-CXCR5-BB515, followed 15 min later by the relevant peptide pools (1 µg/ml/peptide), and a further 1 h later by brefeldin A (1 µg/ml, Sigma-Aldrich) and monensin (0.7 µg/ml, BD Biosciences). Negative control wells contained equivalent DMSO. After 9 h, cells were washed in FACS buffer and

stained with anti-CCR4/CD194–BB700, anti-CCR6/CD196–BUV737, anti-CCR7–APC-Cy7, and anti-CXCR3–BV750 for 10 min at 37 °C. Additional surface stains were performed for 30 min at room temperature in the presence of Brilliant Stain Buffer Plus (BD Biosciences). Viable cells were identified by exclusion using a LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Thermo Fisher Scientific). Cells were then washed in FACS buffer and fixed/permeabilized using a FoxP3 Transcription Factor Staining Buffer Set (Thermo Fisher Scientific). Intracellular stains were performed for 30 min at room temperature. Stained cells were washed in FACS buffer, fixed in PBS containing 1% PFA (Biotium), and acquired using a FACSymphony A5 (BD Biosciences). All flow cytometry reagents are detailed in Supplementary Table 2.

Data analysis and statistics

All samples from each cohort were randomly assigned and analyzed with wildtype and omicron variant peptides in the same experiment. Flow cytometry data were analyzed using FlowJo version 10.8.0 (FlowJo LLC). Stimulation indices were calculated as fold change in frequency relative to the negative control (equivalent DMSO). Positive responses were identified using a threshold stimulation index >2 to exclude background or non-specific responses. Only memory populations were included for the analysis of spike-specific responses by the exclusion of the naive subset (CD45RA⁺CCR7⁺). Data exclusion criteria were established before all experiments. The Investigators were not blinded to allocation during experiments and outcome assessment. Statistical analyses were performed using Prism version 9 (GraphPad). Significance between paired groups was assessed using two sided Wilcoxon signed rank tests. Functional profiles were deconvoluted using Boolean gating in FlowJo version 10.8.0 (FlowJo LLC) followed by downstream analyses in SPICE version 6.1 (<https://niaid.github.io/spice/>).

Data availability statement

All requests for raw and analyzed preclinical data and materials will be promptly reviewed by the corresponding author (M.B.) to determine if they are subject to intellectual property or confidentiality obligations. Any data and materials that can be shared will be released via a material transfer agreement (requested to M.B.). Personal data underlying this article cannot be shared publicly as they are sensitive. Enquiries regarding data availability should be directed to marcus.buggert@ki.se.

Methods reference

1. Bergman, P., *et al.* Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. *EBioMedicine* **74**, 103705 (2021).

Corresponding author(s): Marcus BuggertLast updated by author(s): Jan 13, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

☐	☒	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒	The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☒	☐	A description of all covariates tested
☒	☐	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒	For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i>
☒	☐	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐	Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection Flow cytometry data was collected using a BD FACSymphony A5 flow cytometer.

Data analysis Flow cytometry data was analyzed using FlowJo (Version 10.8.0) and GraphPad Prism (Version 9.0.0). Polyfunctional analysis was performed using SPICE (Version 6) (available at <https://niaid.github.io/spice/>).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All requests for raw and analyzed preclinical data and materials will be promptly reviewed by the corresponding author (M.B.) to determine if they are subject to intellectual property or confidentiality obligations. Any data and materials that can be shared will be released via a material transfer agreement (requested to M.B.). Personal data underlying this article cannot be shared publicly as they are sensitive. Enquiries regarding data availability should be directed to marcus.buggert@ki.se.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	With a sample size of $n = 20$ per group, the probability is 80% that the study will detect a relationship between the independent and the dependent variables at a two-sided 0.05 significance level, if the true change in the dependent variables is 0.663 standard deviations per one standard deviation change in the independent variable. Based on previous experience (Sekine et al, 2020, Cell etc), it should therefore be possible to detect group differences. The total number of individuals from each cohort were selected to match as closely as possible and be approximately twice as high as our power analysis. Vaccinated $n = 40$. Convalescent $n = 48$. Seronegative $n = 48$.
Data exclusions	Individuals with a stimulation index less than 2 were excluded from downstream phenotypic and functional analyses to minimise analysis of background or non-specific responses. Only memory populations were included for the analysis of spike-specific responses by the exclusion of the naive subset (CD45RA+CCR7+). Data exclusion criteria were established before all experiments, similar to before Niessl et al, 2020, Science Immunol etc).
Replication	Given limited sample availability, replication was not performed.
Randomization	Individuals were randomly analyzed. However, WT and Omicron peptides were supplemented in the same experiments to avoid intra-individual experimental differences of T cell responses against the different viral variants.
Blinding	Investigators were not blinded. The data generation for all samples within the same cohort were run in parallel in single experiments.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☐	☒ Human research participants
☒	☐ Clinical data
☒	☐ Dual use research of concern

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☐	☒ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used

AIM assay:
 Fixable Aqua Viability dye Thermo Fisher Cat#L34957 Dilution 3:5000
 BUV805 CD3 BD Biosciences Clone UCHT1 Cat#612895 Dilution 1:50
 BUV496 CD4 BD Biosciences Clone SK3 Cat#612936 Dilution 1:25
 BUV395 CD8 BD Biosciences Clone RPA-T8 Cat#563795 Dilution 1:250
 BV510 CD14 BioLegend Clone M5E2 Cat#301842 Dilution 1:100
 BV510 CD19 BioLegend Clone H1B19 Cat#302242 Dilution 1:100
 BV570 CD45RA BioLegend Clone HI100 Cat#304132 Dilution 1:200
 APC-Cy7 CCR7 BioLegend Clone G043H7 Cat#353212 Dilution 1:50
 PE-Cy7 CD137 BioLegend Clone 4B4-1 Cat#309818 Dilution 1:25
 BV421 CD154 BioLegend Clone 24-31 Cat#310824 Dilution 1:25
 BB700 CD194 BD Biosciences Clone 1G1 Cat#566475 Dilution 1:50
 BUV737 CD196 BD Biosciences Clone 11A9 Cat#612780 Dilution 1:500
 BB515 CXCR5 BD Biosciences Clone RF8B2 Cat#564624 Dilution 1:100
 Unconjugated CD40 Miltenyi Biotec Clone HB14 Cat#130-094-133 Dilution 1:200
 BV650 CD69 BioLegend Clone FN50 Cat#310934 Dilution 1:50

AF647 CXCR3 BioLegend Clone G025H7 Cat#353712 Dilution 1:200
 Intracellular staining:
 Fixable Aqua Viability dye Thermo Fisher Cat#L34957 Dilution 3:5000
 BUV805 CD3 BD Biosciences Clone UCHT1 Cat#612895 Dilution 1:250
 BUV496 CD4 BD Biosciences Clone SK3 Cat#612936 Dilution 1:25
 BUV395 CD8 BD Biosciences Clone RPA-T8 Cat#563795 Dilution 1:250
 BV510 CD14 BioLegend Clone M5E2 Cat#301842 Dilution 1:100
 BV510 CD19 BioLegend Clone HIB19 Cat#302242 Dilution 1:100
 BV570 CD45RA BioLegend Clone HI100 Cat#304132 Dilution 1:200
 APC-Cy7 CCR7 BioLegend Clone G043H7 Cat#353212 Dilution 1:50
 PE-Cy7 CD137 BioLegend Clone 4B4-1 Cat#309818 Dilution 1:100
 BV421 CD154 BioLegend Clone 24-31 Cat#310824 Dilution 1:25
 BB700 CD194 BD Biosciences Clone 1G1 Cat#566475 Dilution 1:50
 BUV737 CD196 BD Biosciences Clone 11A9 Cat#612780 Dilution 1:500
 BB515 CXCR5 BD Biosciences Clone RF8B2 Cat#564624 Dilution 1:100
 BUV563 CD69 BD Biosciences Clone FN50 Cat#748764 Dilution 1:200
 BV785 CD107a BioLegend Clone H4A3 Cat#328644 Dilution 1:500
 BV750 CXCR3 BD Biosciences Clone 1C6 Cat#746894 Dilution 1:50
 BB790 Granzyme B BD Biosciences Clone GB11 Cat#624296 Dilution 1:500
 PE IFN- γ BioLegend Clone B27 Cat#506507 Dilution 1:400
 PE-Dazzle594 IL-2 BioLegend Clone MQ1-17H12 Cat#500344 Dilution 3:100
 BV711 PD1 BioLegend Clone EH12.2H7 Cat#329928 Dilution 1:25
 BV650 TNF BD Biosciences Clone MAb11 Cat#563418 Dilution 3:500

Validation

All antibodies are validated by their respective manufacturers and are quality control tested by surface or intracellular immunofluorescent staining with flow cytometric analysis. For more information on the antibodies used, please visit biolegend.com, bdbiosciences.com, thermofisher.com and miltenyibiotec.com.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics

Among the 40 vaccinated individuals, all were adults with an age range of 22-79 (median age of 53), with females comprising 58%. All 48 convalescent patients confirmed by positive RT-PCR results for SARS-CoV-2 fell within the age range of 44-68 years (median age of 56), with 23% of them being females. Personal information of all 48 individuals with seronegative for SARS-CoV-2 is not available. Population characteristics of each cohort were not considered and did not factor in for inclusion into this study.

Recruitment

The vaccinated healthy individuals were recruited between Feb-March 2021 at Karolinska University Hospital, Sweden in a clinical trial (EudraCT no. 2021-000175-37). Most of the healthy individuals were family members of the study participants with immunocompromised disorders (not included in the present study), recruited to the trial for COVID-19 vaccination. Inclusion criteria for healthy individuals were individual ≥ 18 years, no known immunosuppressive disease or treatment with significant co-morbidity according to the investigator's judgement. The exclusion criteria were previous or ongoing COVID-19, presence of coagulation disease, planned to receive other vaccine within 14 days prior to the first dose of the study vaccine or receive other vaccine from the time of the first study vaccine dose until 14 days after the second dose of study vaccine, pregnancy or breast-feeding, hypersensitivity to any of the active substance in the vaccine, cannot comprehend the information given to study participants for consent, or individuals of any other reasons judged by the investigator to be not suitable for inclusion in the study. One potential selection bias could be the participants willingness for COVID-19 vaccination and serial venipuncture performed in this study, but it is unlikely that this could have impacted any of the results in this study significantly.

The convalescent individuals have been tested positive for SARS-CoV-2 infection during March-April 2020 at Karolinska University Hospital. Patients with severe COVID-19 have been hospitalized, while those with mild COVID-19 have been followed-up at the outpatient clinic of the department of Infectious Diseases, Karolinska University Hospital. The patients were recruited while in the convalescence phase, with blood samples in this study collected at 9 months after the verified SARS-CoV-2 infection. One potential selection bias could be the participants willingness for serial venipuncture or other features associated with individuals who declined enrollment into our study, but it is unlikely that this could have impacted any of the results significantly.

Seronegative samples were acquired from healthy blood donors in late 2020.

All study participants provided written informed consent. All study participants were volunteers.

Ethics oversight

The vaccinated cohort was approved by the Swedish Medical Product Agency (ID 5.1-2021-5881) and the Swedish Ethical Review Authority (ID 2021-00451). Other cohorts were approved by the Regional Ethics Committee in Stockholm, Sweden.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Cryopreserved PBMC
Instrument	BD FACSymphony A5
Software	FlowJo version 10.8.0
Cell population abundance	No sorting was performed.
Gating strategy	Gating strategies are shown throughout the figures. Briefly, lymphocytes were gated by standard FSC/SSC gating followed by singlet discrimination. Viability staining was used to gate live cells. T cells were gated by CD3 expression and no expression of the lineage markers CD19 and CD14. CD4 and CD8 T cells were identified by CD4 and CD8 staining. Naive cells with CD45RA and CCR7 high expression were gated out. Within the remaining population, spike-specific CD4 and CD8 responses were identified by coexpression of CD69/CD154 or CD69/CD137 respectively.

- ☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.